Clinical trials: Migraine in Adults
Migraine
MLD10 in the Prevention of Migraine in Adults
This is a double-blind, placebo-controlled, randomized, multi-center study. Subjects agreeing to participate in the study and meet the entry criteria assessed at the screening visit, will begin a 28 day baseline period to confirm…
- Trial name
- NCT02322333
- Testing
- MLD10
- Where
- 9 sites in United States
- Volunteers
- 157 people
- Sponsor
- Pharmalyte Solutions LLC
Migraine Disorders, Brain, Healthy Adult Participants
Effect of Atogepant on the Vestibulo-Ocular Reflex in Healthy Adults and Adults With Migraine
Researchers want to find out how a substance in the body called CGRP affects balance. CGRP (calcitonin gene-related peptide) is a small protein involved in migraine. Several approved migraine medicines work by blocking it.
- Conditions
- Migraine Disorders, Brain, Healthy Adult Participants, Vestibulo-Ocular Reflex
- Trial name
- VOR-GRIP (NCT07826910)
- Testing
- Atogepant 60 mg
- Where
- Switzerland
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Konrad Peter Weber
Migraine
An Observational Study to Assess Ubrogepant Tablets and Atogepant Tablets to Treat Migraine in Adult Participants
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound.
- Trial name
- COBRA (NCT05827887)
- Where
- 11 sites in Israel
- Volunteers
- 226 people
- Sponsor
- AbbVie
Migraine
DP-VPA for Migraine Prophylaxis, a Pilot Efficacy Study
The study will evaluate if DP-VPA, a derivative of valproate (a drug that is commonly used for the prevention of migraine attacks), can reduce the rate of migraine attacks.
- Trial name
- NCT00640965
- Testing
- DP-VPA
- Where
- 6 sites in Israel
- Volunteers
- 40 people
- Sponsor
- D-Pharm Ltd.
Chronic Migraine
BOTOX® vs. XEOMIN® for Chronic Migraine
Chronic migraine (CM) is a disabling disorder that sidelines active duty personnel and diminishes their quality of life. It affects 1.3% to 2.4% of the general population.
- Trial name
- NCT05598723
- Testing
- IncobotulinumtoxinA (XEOMIN®), OnabotulinumtoxinA (BOTOX®)
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- Naval Medical Center Camp Lejeune
Migraine Disorders, Migraine, Acute
TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults
Study TRX109011/TRX109013, A Randomized, Double-blind, Double-dummy, Placebo-controlled, Crossover Study to Evaluate the Efficacy of TREXIMET® (Sumatriptan + Naproxen Sodium) versus Butalbital-containing Combination Medications…
- Trial name
- NCT00573170
- Testing
- TREXIMET®, Butalbital-containing Combination Medications (BCM)
- Where
- 107 sites in United States
- Volunteers
- 375 people
- Sponsor
- GlaxoSmithKline
Migraine
Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications
This study is being conducted to evaluate the efficacy and tolerability of rimegepant for migraine prophylaxis in adults with a history of inadequate response to oral preventive medications
- Trial name
- NCT05518123
- Testing
- Rimegepant
- Where
- 111 sites in United States, Australia and 12 more
- Volunteers
- 962 people
- Sponsor
- Pfizer
Migraine
Home-based Biofeedback for the Prevention of Migraine
The goal of this clinical trial is to test an app-based biofeedback treatment in adults with migraine. The aim of the study is to investigate the safety and effectiveness of biofeedback treatment using the medical device Cerebri…
- Trial name
- BioCer (NCT05616741)
- Testing
- Cerebri biofeedback, Cerebri headache diary
- Where
- 4 sites in Norway
- Volunteers
- 279 people
- Sponsor
- Nordic Brain Tech AS
Episodic Migraine
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing episodic migraine.
- Trial name
- E-BEOND (NCT06047457)
- Testing
- Botulinum toxin type A
- Where
- 105 sites in United States, Canada and 6 more
- Volunteers
- 751 people
- Sponsor
- Ipsen
Acute Treatment of Migraine
A Study to Find Out if the Medicine Called Rimegepant is Safe for Adults in India
This is a multicenter, single-arm, open-label Phase 4 study evaluating the safety and tolerability of rimegepant 75 mg orally disintegrating tablet (ODT) for the acute treatment of migraine (with or without aura) in adult…
- Trial name
- NCT07685769
- Testing
- Rimegepant 75 mg ODT
- Where
- 7 sites in India
- Volunteers
- 60 people
- Sponsor
- Pfizer
Migraine
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
A migraine is a moderate to severe headache typically on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms.
- Trial name
- UBRO MM (NCT06417775)
- Testing
- Ubrogepant
- Where
- 106 sites in United States, Puerto Rico
- Volunteers
- 496 people
- Sponsor
- AbbVie
Chronic Migraine
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine
Migraine is characterized by attacks of throbbing, moderate or severe headache, often associated with nausea, vomiting, and/or sensitivity to light and/or sound.
- Trial name
- ATO-BOTOX (NCT05216263)
- Testing
- Atogepant
- Where
- 29 sites in United States
- Volunteers
- 75 people
- Sponsor
- AbbVie
Migraine
Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults
The goal of this clinical trial is to learn if drug MTX101 works to treat acute migraine attacks in adults. It will also learn about the safety of the drug MTX101.
- Trial name
- NCT06728553
- Testing
- MTX101
- Where
- 7 sites in United States
- Volunteers
- 78 people
- Sponsor
- Manistee Therapeutics
Migraine
Ascending Single Doses of Erenumab (AMG 334) in Healthy Adults and Migraine Patients
The primary purpose of this study is to determine whether erenumab is safe and well tolerated in healthy adults and migraine patients.
- Trial name
- NCT01688739
- Testing
- Erenumab
- Where
- Belgium
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Amgen
Migraine
Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens
The purpose of this study is to compare the efficacy and safety of daily and every other day dosing of rimegepant to placebo as a preventive treatment for episodic migraine.
- Trial name
- NCT05217927
- Testing
- Rimegepant 75mg daily dosing, Rimegepant 75mg every other day dosing
- Where
- 107 sites in United States, Austria and 8 more
- Volunteers
- 1,415 people
- Sponsor
- Pfizer
Migraine
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound.
- Trial name
- CORNERSTONE (NCT06543914)
- Where
- 112 sites in United States, Belgium and 12 more
- Volunteers
- 1,314 people
- Sponsor
- AbbVie
Migraine
Mindfulness and Mechanisms of Pain Processing in Adults With Migraines
Although many adults with migraines use non-pharmacological treatment options, there is a lack of research on the use of many mind/body techniques specifically for headache.
- Trial name
- NCT02695498
- Testing
- Mindfulness Based Stress Reduction, Migraine/stress Education
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Wake Forest University Health Sciences
Migraine
Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
This study is being conducted to evaluate the efficacy and tolerability of rimegepant in a population of adults that are unsuitable for triptan medications due to a previous intolerance, lack of efficacy, or contraindication…
- Trial name
- NCT05509400
- Testing
- Rimegepant
- Where
- 93 sites in United States, Australia and 13 more
- Volunteers
- 813 people
- Sponsor
- Pfizer
Migraine
Efficacy and Safety of Oral NBP Soft Capsules for the Prevention of Episode Migraine Attacks in Adult Migraine Patients
This is a multicentre, randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of oral butylphthalide soft capsules for the prophylactic treatment of migraine in adults.
- Trial name
- ENERGY (NCT06968429)
- Testing
- NBP Softgel Capsules
- Volunteers
- 500 people
- Sponsor
- Chinese PLA General Hospital
Migraine, With or Without Aura
Efficacy and Safety of BR005-036C Tablets for the Acute Treatment of Migraine in Adults
The purpose of this study is to compare the efficacy and safety of BR005-036C versus placebo in subjects with Acute Migraines
- Trial name
- NCT07792681
- Testing
- BR005-036C
- Where
- 83 sites in China
- Volunteers
- 2,079 people
- Sponsor
- Brise Pharmaceuticals Co., Ltd.